Vistin Pharma ASA (VISTN) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Vistin Pharma ASA stock NOK 30.04, price NOK 18.85, upside +59.4%, quality 73 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range kr 9.79 – kr 25.51 · fair‑value band kr 18.15 – kr 39.06 · the kr 18.85 price screens below the kr 30.04 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow Vistin Pharma in your weekly email
Every Wednesday you see whether Vistin Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) in Africa, Europe, Asia, and North and South America.
Show moreShow less
It offers metformin HCl; metformin direct compressible; and metformin premixed with lubricant magnesium stearate for use in plain metformin immediate release tablets. The company was founded in 1969 and is based in Oslo, Norway.
Stock analysis
Vistin Pharma ASA (VISTN) currently trades at kr 18.85, while our model-based Fair Value estimate is kr 30.04, implying the stock looks roughly 37% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of kr 31.54 per share, and 18 of the 26 models we run sit above the kr 18.85 price.
Bear case: the Economic Profit group reads lowest at kr 15.72, and 8 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: kr 18.15 (bear) to kr 39.06 (bull), the price of kr 18.85 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 73/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Vistin Pharma ASA reported revenue of 452M NOK in FY2025 versus 279M NOK in FY2021, a compound +12.9%/yr. Reported net income was 74.8M NOK in FY2025, compounding +31.6%/yr from FY2021.
Key figures
Market cap 836M NOK (≈ $88.5M) Micro · P/E ratio 11.9 · P/S ratio 1.94 · EPS (TTM) kr 1.58 · Dividend yield 8.0% · Net margin 16.3% · Return on equity 22.9% · Return on assets (EBIT) 13.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 73 out of 100 (low confidence).
What moves the price
The share trades about 15% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 59%, VISTN screens cheaper than that median.
Fair Value models
Bearkr 18.15Fair Value kr 30.04Bullkr 39.06
Price kr 18.85 · Upside +59.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (kr 0.0686 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.96/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+5.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.3%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.4%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+30.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+22.7%
Dividend (yield on the price)8.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.10.4% vs 8.3%, steady
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 20%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+5.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Norway: IMF forecast 2.4% a year to 2030, 3.3% from 2016 to 2025) that is about +2.8% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score73 · Top 25%
Fair Value upside+59.4% · Top 25%
Profitability
Return on equity (12 months)22.9% · Top 25%
Return on assets17.0% · Top 25%
Net margin (12 months)16.3% · Top 25%
Operating margin (12 months)16.0% · Above median
Growth and dividend
Revenue growth (quarter YoY)−14.8% · Bottom 25%
Dividend yield (12 months)8.0% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)11.9× · Cheapest 25%
P/B2.54× · Pricier than median
P/S (12 months)1.94× · Cheaper than median
Price / free cash flow (fiscal year)13.6× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Vistin Pharma ASA (VISTN) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of kr 30.04 versus a price of kr 18.85, about +59% upside (undervalued).
What is the fair value of VISTN?
Our model-based fair value for Vistin Pharma ASA is kr 30.04 (as of Nov 4, 2026), built from audited fundamentals. The current price: kr 18.85.
What is the quality score of VISTN?
Vistin Pharma ASA has a Quality Score of 73/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vistin Pharma ASA (VISTN)?
Our model-based price target is the fair value of kr 30.04 (as of Nov 4, 2026) from 26 valuation models. Cautious scenario kr 18.15, optimistic scenario kr 39.06. It is a calculation from audited fundamentals, not an analyst target.
What is the Vistin Pharma ASA stock forecast for 2026?
Our models put fair value at kr 30.04, about +59% upside versus a price of kr 18.85 (undervalued). Cautious scenario kr 18.15, optimistic scenario kr 39.06. The calculation is refreshed regularly with new filings.
What is the revenue of Vistin Pharma ASA (VISTN)?
Vistin Pharma ASA reported trailing-twelve-month revenue of about 432M NOK (latest available figure, as of Nov 4, 2026).
Does Vistin Pharma ASA pay a dividend?
Vistin Pharma ASA currently shows a dividend yield of 7.96% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of Vistin Pharma ASA (VISTN) and when is the ex-dividend date?
Vistin Pharma ASA pays a dividend of kr 1.50 per share a year, a dividend yield of 8.0%. The next ex-dividend date is Nov 24, 2026. The payout ratio is 94.9% of earnings. Free cash flow covers the dividend 0.92 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into Vistin Pharma ASA (VISTN)?
For today's price to be fair in a discounted-cash-flow model, Vistin Pharma ASA would have to grow free cash flow by +5.2 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.3 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of VISTN use?
Our models discount Vistin Pharma ASA at 11.2 %: a base by market capitalisation (micro), damped by beta 0.58, country premium for Norway. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Vistin Pharma ASA that is +5.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has Vistin Pharma ASA (VISTN) delivered so far?
Over the past 5 years revenue at Vistin Pharma ASA grew +12.3 % a year. The price currently implies free-cash-flow growth of +5.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Vistin Pharma ASA (VISTN) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Vistin Pharma ASA (+5.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Vistin Pharma ASA (VISTN)?
The free-cash-flow yield on the price is 7.34 %: that much free cash flow Vistin Pharma ASA produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Vistin Pharma ASA (VISTN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vistin Pharma ASA it is kr 30.04 per share (as of Nov 4, 2026), against a price of kr 18.85. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Vistin Pharma ASA stock overvalued or undervalued in 2026?
As of Nov 4, 2026, VISTN trades below its calculated fair value: price kr 18.85, fair value kr 30.04, a gap of about +59% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VISTN?
No. The price is what the market pays today (kr 18.85); the fair value is what the company's own numbers justify (kr 30.04). For Vistin Pharma ASA the two are kr 11.19 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vistin Pharma ASA worth?
The market values Vistin Pharma ASA at about 836M NOK (market capitalisation, as of Nov 4, 2026). Per share that is kr 18.85; our models calculate a fair value of kr 30.04 per share.
What do the bullish and bearish scenarios say about VISTN?
Our models span a range for Vistin Pharma ASA: cautious scenario kr 18.15, base kr 30.04, optimistic kr 39.06 per share (as of Nov 4, 2026, price kr 18.85). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of VISTN?
Vistin Pharma ASA trades at a price-to-earnings ratio of 11.9 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 30.04 is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2016 to 2025), reported earnings: 16.8. Other multiples: P/B 2.5, P/S 1.9, EV/EBITDA 8.0.
How solid is the balance sheet of Vistin Pharma ASA (VISTN)?
Balance-sheet figures for Vistin Pharma ASA (as of Nov 4, 2026): return on equity 22.9%. They feed the Quality Score of 73/100, which measures business quality independently of the share price.
How far is VISTN from its 52-week high?
Vistin Pharma ASA trades at kr 18.85, about 15% below its 52-week high of kr 22.16 and 5% above the low of kr 18.00 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 30.04 is for.
Which stocks are comparable to Vistin Pharma ASA?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vistin Pharma ASA stock attractive at the current price?
The data as of Nov 4, 2026: price kr 18.85, calculated fair value kr 30.04 (+59%), Quality Score 73/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VISTN calculated?
We run Vistin Pharma ASA through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of kr 30.04 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Vistin Pharma ASA currently trades 37% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vistin Pharma ASA (VISTN)?
The closing price on Nov 6, 2026 was kr 18.85. Our model-based fair value is kr 30.04, about +59% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vistin Pharma ASA right now?
Solid quality (73/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (kr 18.15 to kr 39.06) leaves room in how you read the outcome.
Key figures of Vistin Pharma ASA
How large is the market capitalisation of Vistin Pharma ASA (VISTN)?
The market capitalisation of Vistin Pharma ASA is 836M NOK (≈ $88.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vistin Pharma ASA (VISTN)?
The price-to-sales ratio of Vistin Pharma ASA is 1.94 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vistin Pharma ASA (VISTN)?
Earnings per share at Vistin Pharma ASA are kr 1.58 (price ÷ EPS = P/E 11.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Vistin Pharma ASA (VISTN)?
The dividend yield of Vistin Pharma ASA is 8.0% (payout 94.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Vistin Pharma ASA (VISTN)?
The net margin of Vistin Pharma ASA is 16.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vistin Pharma ASA (VISTN)?
The return on equity (ROE) of Vistin Pharma ASA is 22.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vistin Pharma ASA (VISTN)?
On an EBIT basis the return on assets of Vistin Pharma ASA is 13.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vistin Pharma ASA (VISTN)?
The operating margin of Vistin Pharma ASA is 16.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vistin Pharma ASA (VISTN)?
Revenue at Vistin Pharma ASA is growing −14.8% versus a year earlier (3y avg +16.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vistin Pharma ASA (VISTN)?
Earnings per share at Vistin Pharma ASA are growing −23.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Vistin Pharma ASA (VISTN) carry?
The net debt of Vistin Pharma ASA is 43.7M NOK (fiscal year 2022, ≈ 0.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Vistin Pharma ASA in the live analysis
One click puts Vistin Pharma ASA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 4, 2026